{"date": "2021-11-19 11:16:26.994000+00:00", "ticker": "AMZN", "mrkt_info": {"open": 3549.0, "close": 3676.57}, "html": "<div class=\"storyContent\" lang=\"en\"><style type=\"text/css\">.storyContent * {border-color:inherit !important;outline-color:inherit !important;}</style><div class=\"storyframe\" id=\"storydiv\"><div class=\"TEXT\" id=\"storybody\" name=\"storybody\"><div id=\"storybodycontent0\"><span class=\"storycontent\"><pre>Click the following link to watch video: <a href=\"https://share.newscasts.refinitiv.com/link?entryId=1_chub9afg&amp;referenceId=1_chub9afg&amp;pageId=RefinitivNewscasts\" data-type=\"url video-url\" translate=\"no\">https://share.newscasts.refinitiv.com/link?entryId=1_chub9afg&amp;referenceId=1_chub9afg&amp;pageId=RefinitivNewscasts</a></pre>Source: Edison Investment Research<br/><br/>Description: Legalisation, increasing acceptance of and growing demand for pharmaceutical and consumer products mean the cannabinoids industry is booming. Will biosynthesis take it to new heights?&amp;#xD;&amp;#xD;Writer and journalist Vivienne Parry speaks to Randy Baron of Pinnacle Associates, Roy Lipski of Creo, Trevor Peters of Willow Biosciences and Nick Davis of Memery Crystal as they discuss the opportunity for investors and how biosynthesis will affect the direction of cannabinoids.&amp;#xD;&amp;#xD;This is the cannabinoids conversation you won\u2019t want to miss.&amp;#xD;&amp;#xD;Please click here to watch video: <a href=\"https://www.edisongroup.com/edison-tv/could-cannabinoid-biosynthesis-be-the-next-big-thing-for-investors\" data-type=\"url\" class=\"tr-link\" translate=\"no\">https://www.edisongroup.com/edison-tv/could-cannabinoid-biosynthesis-be-the-next-big-thing-for-investors</a>/<br/>Short Link: <a href=\"https://refini.tv/3FtFv71\" data-type=\"url\" class=\"tr-link\" translate=\"no\">https://refini.tv/3FtFv71</a><br/><br/>Video Transcript:<br/><br/>Verified transcript not available</span></div></div></div></div>"}